News

Several reports suggest that the offer for the takeover bid is about $27bn, which is re-offered to Perrigo after its rejection to the earlier proposal. Mylan is offering

The drug was being tested in children with nonalcoholic steatohepatitis (NASH), which is a liver inflammation caused by a buildup of fat in the liver. The study involved

Both the companies signed license deal in December 2014. The termination starts on 7 January 2016. Anthera will regain all worldwide rights for blisibimod without cost and Zenyaku

In August 2007, PsychoGenics and Sunovion entered into a drug discovery and development agreement to combine their complementary strengths and expertise to screen compound libraries and identify a

It is anticipated that the acquisition will strengthen the company’s foothold in the Proteomics market and provide its customers added flexibility to leverage this exciting technology to model

Study results revealed tens of thousands of patients being treated with opioid therapy as testing positive for non-prescribed, powerful opioids like oymorphone, non-prescribed benzodiazepines like Xanax and illicit

Approved by the FDA on Aug. 27, 2015, Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that reduces

Xtampza ER, Collegium’s lead product candidate, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. The FDA will consider the advisory committees’ recommendation as

Intramuscular vaccinations of VB10.16 will be offered to patients at three different time points. Vaccibody will assess two different dosing schedules in the first phase of the study